These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. [Testosterone-dihydrotestosterone ratio in the differential diagnosis of pancreatic disease]. Sándor Z, Tulassay Z, Bodrogi L, Papp J, Szathmári M, Fehér T. Orv Hetil; 1989 Jun 25; 130(26):1387-8. PubMed ID: 2748159 [Abstract] [Full Text] [Related]
9. Serum testosterone:dihydrotestosterone ratio and CA 19-9 in the diagnosis of pancreatic cancer. Robles-Díaz G, Díaz-Sánchez V, Fernández-del Castillo C, Morales M, Aceves G, Galván E, Altamirano A. Am J Gastroenterol; 1991 May 25; 86(5):591-4. PubMed ID: 2028950 [Abstract] [Full Text] [Related]
12. Androgen levels in the third trimester of pregnancy in patients with preeclampsia. Salamalekis E, Bakas P, Vitoratos N, Eleptheriadis M, Creatsas G. Eur J Obstet Gynecol Reprod Biol; 2006 May 01; 126(1):16-9. PubMed ID: 16139944 [Abstract] [Full Text] [Related]
13. CA 50 compared with CA 19-9 as a serum tumour marker for pancreatic carcinoma. Pasquali C, Sperti C, D'Andrea AA, Costantino V, Filipponi C, Pedrazzoli S. Ital J Gastroenterol; 1994 May 01; 26(4):169-73. PubMed ID: 7949259 [Abstract] [Full Text] [Related]
14. Low serum testosterone/dihydrotestosterone ratio in patients with pancreatic carcinoma. Robles-Diaz G, Diaz-Sanchez V, Mendez JP, Altamirano A, Wolpert E. Pancreas; 1987 May 01; 2(6):684-7. PubMed ID: 3438305 [Abstract] [Full Text] [Related]
15. Evaluation of direct and indirect markers to assess the androgen status in healthy males during aging. Elmlinger MW, Kühnel W, Döller PC. Clin Lab; 2006 May 01; 52(9-10):491-6. PubMed ID: 17078476 [Abstract] [Full Text] [Related]
16. Women with low libido: correlation of decreased androgen levels with female sexual function index. Turna B, Apaydin E, Semerci B, Altay B, Cikili N, Nazli O. Int J Impot Res; 2005 May 01; 17(2):148-53. PubMed ID: 15592425 [Abstract] [Full Text] [Related]
17. Serum levels of vasoactive intestinal peptide (VIP) in patients with adenocarcinomas of the gastrointestinal tract. Hejna M, Hamilton G, Brodowicz T, Haberl I, Fiebiger WC, Scheithauer W, Virgolini I, Köstler WJ, Oberhuber G, Raderer M. Anticancer Res; 2001 May 01; 21(2A):1183-7. PubMed ID: 11396161 [Abstract] [Full Text] [Related]